Weekly channel feed

Ap­ple Tree says its biotechs face ‘im­mi­nent col­lapse’; Ad­vo­cates urge J&J to pro­ceed with eye gene ther­a­py; Ab­b­Vie buys in vi­vo CAR-T mak­er Cap­stan; and more

4 days ago

Sources say FDA com­mis­sion­er sought re­jec­tion of KalVista’s rare dis­ease drug; FDA looks in­to Sarep­ta’s Duchenne ther­a­py af­ter deaths; and more

Last week

FDA un­veils new pi­lot pro­gram; Sage finds a buy­er; Eli Lil­ly to ac­quire Verve; and more

3 weeks ago

RFK re­moves all ACIP mem­bers, names new ones; Na­tion­al Re­silience to close six sites; Deals and fi­nanc­ing re­cap of the week

4 weeks ago

High­lights from #AS­CO25; Biotech’s icy mar­ket; Sanofi’s $9B ac­qui­si­tion; and more

Last month

Pa­tient dies in Rock­et gene ther­a­py tri­al; Lil­ly’s $1B deal for a non-opi­oid pain biotech; A new dawn for psy­che­delics?; and more

Last month

An­a­lyz­ing the End­points 100; ‘Most fa­vored na­tion’ tar­gets re­vealed; Biotech slump makes leas­es a li­a­bil­i­ty; and more

Last month

What we know about ‘most fa­vored na­tion’; GSK’s $1.2B MASH deal; Bay­er de­tails staff cuts; and more

Last month

Makary names Vinay Prasad CBER chief; Q1 earn­ings re­port; More on “Most Fa­vored Na­tions"; and more

2 months ago

Earn­ings sea­son con­tin­ues; FDA de­lays PDU­FA date; AACR re­cap; and more

2 months ago

Earn­ings sea­son is up­on us; Makary on rare dis­ease; Start­up is first to in­ject CRISPR in the brain; and more

2 months ago

Trump’s ex­ec­u­tive or­der on drug pric­ing; Pfiz­er drops oral obe­si­ty drug; Seed rounds at their low­est in years; and more

2 months ago

Biotech’s sur­vival guide; What tar­iffs could mean for phar­ma; Con­gress push­es for $15B fed­er­al biotech in­vest­ment; and more

2 months ago

Staff cuts sweep across FDA; Tar­iff roll­out rais­es ques­tions; The R&D 15 is back; and more

3 months ago

HHS cuts and more from DC; Lyn­dra winds down; 23andMe files for bank­rupt­cy; and more

3 months ago

Teenag­er dies af­ter re­ceiv­ing Sarep­ta ther­a­py; Im­muno­vant gets Phase 3 win, but shifts fo­cus; Al­ny­lam’s big mo­ment; and more

3 months ago

Up­dates on health agency nom­i­nees; New da­ta from Pfiz­er, Beam; MASH start­up weighs IPO; and more

3 months ago

FDA and NIH nom­i­nees sail through Sen­ate hear­ings; Tar­iffs’ ear­ly im­pact on drug man­u­fac­tur­ing; Ab­b­Vie’s move in­to the obe­si­ty mar­ket; and more

4 months ago

The top 100 biotech in­vestors; FDA vac­cine meet­ing can­celed; Can Bill An­der­son save Bay­er?; and more

4 months ago

Bourla prais­es Trump as RFK Jr. preps vac­cine re­view; Will CRISPR mat­ter?; Atom­wise hires new CEO; and more

4 months ago

Up­dates from Wash­ing­ton; A trio of Big Phar­ma deals; What do re­cent share buy­backs mean for M&A?; and more

4 months ago

Q4 earn­ings up­dates; Bio­gen de­tails re­vised re­search strat­e­gy; RFK Jr. ad­vances out of Sen­ate com­mit­tee; and more

5 months ago

RFK Jr. hear­ings leave key GOP sen­a­tor “strug­gling”; Drug­mak­ers re­port Q4 earn­ings; Leerink builds health­care M&A team; and more

5 months ago

Bio­gen par­ing back re­search ef­forts; Will Chi­nese biotechs threat­en US dom­i­nance?; What the new ad­min­is­tra­tion means for phar­ma ; and more

5 months ago
1234 Next page Last page
A service from the Financial Times